Login / Signup

Phase 1b study of pan-AKT inhibitor vevorisertib alone or with paclitaxel or fulvestrant in PIK3CA/AKT/PTEN-mutated advanced solid tumors.

Shubham PantErika HamiltonSusanna V UlahannanJames F StraussFadi S BraitehMo HuangDanny Chih Hsun Liaw
Published in: Cancer (2023)
ClinicalTrials.gov, NCT02761694.
Keyphrases
  • cell proliferation
  • signaling pathway
  • pi k akt
  • protein kinase
  • wild type